EXAS

$EXAS chatter on StockTwits

• 
  David Shapiro@B2iDigitalJun 16

  Phio Pharmaceuticals Corp. PH-762 silences PD-1 inside a tumor to help the immune system attack cancer. Robert Bitterman, President and CEO of Phio Pharmaceuticals Corp. (NASDAQ: $PHIO ), used a Force Family Office webinar to explain how the company's lead candidate, PH-762, works. The drug targets PD-1, a protein that tumors use to switch off the immune system's T cells, by silencing the gene that produces it so those T cells can recognize the tumor and attack it. Phio Pharmaceuticals Corp. is a B2i Digital Featured Company. See the company's profile at https://b2idigital.com/phio-pharmaceuticals Bitterman walked through what happens once PH-762 is injected: "...what we do is we're turning off the signal from the gene that's producing the protein, the PD-1. In the absence of PD-1, the T-cells have the ability to basically recover, to reinvigorate, and to go about recognizing the tumor and attack it, which is what a normal healthy immune system will do to a foreign invader." The webinar also covered: • PH-762 as a short interfering RNA (siRNA) injected directly into a tumor, part of Phio's INTASYL® platform • How silencing PD-1 is designed to reinvigorate T cells so they recognize and attack the tumor • Dr. Mary Spellman's point that treating locally right at the lesion and may mean fewer systemic side effects • Bitterman's comparison of the approach to shutting off a water faucet at its source Watch the full presentation: https://youtu.be/QTVd5xDCgGE Phio Pharmaceuticals is a clinical stage biotechnology company developing immuno oncology therapeutics using its INTASYL® self delivering RNAi platform, led by President and CEO Robert Bitterman. Its lead candidate, PH-762, silences designated genes to make immune cells more effective against cancer cells. Learn more at https://phiopharma.com. For investor information, visit https://phiopharma.com/investors/. Discover more emerging growth Featured Companies, industry-leading Featured Experts, and upcoming Featured Conferences at https://b2idigital.com. Disclosure: B2i Digital is not a broker-dealer or investment adviser. This post is informational and not an offer or solicitation regarding any security. $EXAS, $NTRA, $GH, $XBI

  View on StockTwits ↗
• 
  Steve@Woodman7Jun 12

  @dmc4321 @oaksapollo - I was a longtime $EXAS fan and loved the company and the stock. It was my #1 holding for years and I bought all the dips along the way. Even though I made a lot of money off the stock and hundreds of calls I had at the time I was disappointed when they sold to $ABT because I wanted to see them more fully achieve their destiny as a stand alone company/stock. However, I say all this just to say that you never know what will happen. Value is value. It WILL bubble to the surface. Exact grew to a point where the logical next step was to merge with a much larger player that could use its reach and resources to take it to an even greater place. How the value of $LUCD gets monetized is TBD at this point. But it does have great value imho, esp vs the current market price. They may not have to slug it out for years to get traction and scale. They may simply partner up, sell rights, merge, get taken private, etc…But one way or another, the value will emerge.

  View on StockTwits ↗
• 
  julian jakobi@julianjakobiBullishJun 5

  $BLGO Why I own 1.25% of $BLGO - full DD (link below) Wrote this for family after a long discussion with a retired doctor about why I keep adding despite weak sentiment. I recently added another $40K. This isn’t hype-it’s conviction built over years of research, criticism, and experience. I’ve seen setups like this before ($EXAS From multi year lows → 2000%+), where the story looked worst before it works. BioLargo, in my view, is deeply misunderstood. Clean water, clean air, advanced wound care, lithium-free batteries-real problems, real tech. The best opportunities are uncomfortable, unpopular, and doubted. That’s exactly why I’m here. TL;DR: will be here until the whole success story will have unfolded. We know what is coming. IMHO a screaming strong buy at $36 Million Market Cap. Safe download link to Full 26 pages DD: https://drive.google.com/file/d/133fUlR-Mu_SXFzdthMuSeE_7ZPPkm1_q/view

  View on StockTwits ↗
• 
  Lynker@GordoHLYK13May 20

  $NEO Back in 2018 I held 1k shares of NeoGenomics at a $13 average and watched it run to $60. Fast forward to 2026… now I’m holding 4k shares at $8.56 and the setup honestly looks even stronger. NEO today isn’t the same company from 2018 — bigger revenue, deeper oncology relationships, more advanced molecular testing, AI-driven diagnostics, and expanding precision medicine exposure. While everyone chases hype, NEO is quietly building a real cancer diagnostics powerhouse. The business is making substantially more money than it was during the last major run, yet the stock trades at a fraction of those levels. If execution keeps improving and margins expand, this could easily feel like NeoGenomics 4.0. 🚀 $NEO making way more money than the 2018 run to $60… yet trading near $8. Different beast now — stronger tech, bigger oncology footprint, AI diagnostics growth, and huge upside if sentiment flips. NeoGenomics 4.0 loading. 🔥 $TEM $NTRA $GH $EXAS

  View on StockTwits ↗
• 
  William S Burroughs@DoctrBenwayBullishMay 12

  $GERN Uptake takes time. Stay long and the numbers continually become more compelling as hematologists (prone to inertia until something is proven compellingly better) change their practice in MDS/MF. Analogy: I knew Cologuard would have uptake and bought tons of $EXAS in the $4 range, I knew low risk patients would eschew a prep and procedure once the diagnostic follow-up was covered.

  View on StockTwits ↗
• 
  Enjoy Life@Enjoy_Life_BroMay 8

  $ABT $EXAS and poor leadership killed this. Not recovering any time soon

  View on StockTwits ↗
• 
  malphius@malphiusBullishMay 8

  $EXAS Did you know there is an overlap with $HUMA and the board of directors? Did you know that 1 share of EXAS will buy 100 shares of $HUMA right before their June 11 V012 Phase 3 catalyst to unlock the Dialysis market?

  View on StockTwits ↗
• 
  Austin@StockprofilerBullishMay 6

  $VNRX New Article. VolitionRx is stacking catalysts heading into Q4 2026 — finger-prick sepsis detection, French reimbursement, a $5M vet milestone, and licensing talks with 10 major diagnostics players. Revenue up 40%. Not financial advice. DYOR. https://allcapresearch.com/f/volitionrx-vnrx-stacking-catalysts-into-q4-2026 $EXAS $ILMN $PACB $NTRA

  View on StockTwits ↗
• 
  Enjoy Life@Enjoy_Life_BroMay 5

  $ABT Grossly overpaid for $EXAS . Now employees and shareholders suffer. Do something leadership!!!!

  View on StockTwits ↗
• 
  Professional Pattern Trader@FundaTechMay 1

  $ABT The acquisition of $EXAS was a very good strategic deal that refreshes its diagnostics story and bets on secular tailwinds in oncology/prevention. Near-term pain (dilution, stock reaction) is typical for large accretive-over-time acquisitions, but the +3B sales addition and margin/synergy upside support long-term value if integration succeeds. Many analysts see it enhancing Abbott’s growth profile.

  View on StockTwits ↗
• 
  Lynker@GordoHLYK13Apr 29

  $NEO $EXAS $GH $NTRA $NEO move is no pump n dump — this is what a real fundamental breakout looks like. 🚀 NEO ripping premarket is a direct reaction to legit catalysts, not hype: 🔥 Q1 Earnings Beat • Revenue came in at $187M, beating Wall Street • Clinical revenue up 14% YoY • High-margin NGS revenue exploded 26% • Management RAISED 2026 guidance to $797M–$803M 🔥 Analyst Upgrades Rolling In • Leerink upgraded to Outperform and doubled PT from $12 to $25 • Benchmark also upgraded to Buy 🔥 MolDX Approval PanTracer liquid biopsy getting reimbursement support is a game changer — opens the door for recurring revenue and lowers risk big time. 💰 Heavy volume + better numbers + raised guidance + analysts chasing = smart money stepping in. This isn’t a pump… this is institutions repricing NEO higher. 📈

  View on StockTwits ↗
• 
  julian jakobi@julianjakobiBullishApr 23

  @TradesBB that’s what happens when your 2000% gain shares get automatically sold a couple of weeks ago as that $EXAS company was taken over. Freed up some funds. 🤑 I made a new account just for putting cheap BioLargo shares in it. Already 125k + shares strong. Crossed the 4 million shares mark and counting. 100% conviction- No Guts - No Glory!

  View on StockTwits ↗
• 
  Stocktwits News@StocktwitsNewsApr 17

  LCID, ABT, ASBP Stocks Hit 52-Week Lows Today: What’s Driving The Selloff? $LCID $ABT $ASBP $EXAS https://stocktwits.com/news/equity/markets/why-lcid-abt-asbp-stocks-hit-52-week-lows-today/cZJUhKPRIxB

  View on StockTwits ↗
• 
  Bond@xx007xxBullishApr 9

  @chuckjackson @erevnon it’s not a comparison on technology. Take a look at the multiple taken by Abbott acquiring $EXAS The point is we haven’t seen multiples like this acquiring companies in a LONG time. Usually a 100-150% premium. I’m well aware of what they are

  View on StockTwits ↗
• 
  Hafa*Adai@CNMI670Apr 2

  KALV / PHVS potential big pharma acquisitions for hereditary angioedema (HAE) treatments. $APLS $DAWN $FOLD $EXAS $CNTA . BEP energy play.

  View on StockTwits ↗

Recent $TICKER stream from stocktwits.com — refreshed every 5 minutes. Sentiment tags are self-reported by posters. Not investment advice.